Valion Bio (VBIO) shares rose 47% to $4.12 on Tuesday after the company announced it successfully formulated an oral mucosal version of its lead drug candidate Entolimod alongside Shear Kershman Laboratories, a development the company says could expand its long-term commercial opportunity.
What happened
On September 30, Valion Bio issued a press release via AccessWire announcing that its research partnership with Shear Kershman Laboratories had achieved successful formulation of oral mucosal Entolimod. The announcement characterized the achievement as a milestone that could significantly widen the potential applications and commercial scope of the drug candidate.
The news follows an August announcement that Ukraine's Ministry of Health had advanced the Entolimod dossier into a formal technical assessment phase under a regulatory equivalence pathway. Valion Bio has been pursuing multiple international regulatory paths for the drug, which is also being studied under U.S. government-funded programs.
Why the stock moved
The announcement from AccessWire on September 30 represented a concrete, measurable development in Valion Bio's pipeline. Successful formulation of an oral mucosal delivery system for Entolimod addresses a practical challenge in drug delivery that could broaden patient accessibility and commercial viability.
Entolimod is a TLR5 agonist targeting acute radiation syndrome, a condition of particular interest to biodefense programs. The company has disclosed ongoing work funded by U.S. government agencies including AFRRI and NIAID, which designed a proprietary protocol to evaluate Entolimod as a treatment for GI-ARS. The drug is also being studied for oncology-related applications and chronic immunological conditions.
Valion Bio noted in its announcement that the oral formulation could multi-fold expand the long-term opportunity for Entolimod, language that signals significant commercial potential beyond the existing development scope.
The numbers
VBIO closed at $2.81 on Monday and traded as high as $4.12 during Tuesday's session, representing a 46.62% intraday gain. Trading volume reached approximately 31.9 million shares, compared to the stock's average daily volume of roughly 136,500 shares based on short interest data. This volume reflects extraordinary interest, running approximately 234 times the typical daily turnover.
The company's market capitalization stands near $13.2 million, with a float of approximately 3.07 million shares and 3.2 million total shares outstanding.
Valion Bio regained compliance with NASDAQ's minimum bid price requirement in September following prior delisting risk. The company also appointed life sciences veteran Dean Zikria as interim CEO and announced board leadership changes in late September.
What to watch
The oral mucosal formulation announcement marks a development-stage milestone, but investors should track advancement toward clinical or commercial stages. Progress on Ukraine's regulatory review, which accepted the Entolimod dossier for formal review in July, could represent a near-term catalyst. Results from U.S. government-funded studies targeting GI-ARS will also provide insight into the drug's efficacy data under the PBI-BM2.5 protocol designed by AFRRI and NIAID.
The company's CDMO services and broader immunology pipeline, including Entolasta for chronic applications, represent additional value drivers beyond the acute radiation syndrome indication.